Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Stuttgart - Delayed Quote • EUR Karolinska Development AB (2I9.SG) Follow Add holdings 0.0636 +0.0006 +(0.95%) At close: April 25 at 8:05:35 AM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 2I9.SG 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 2I9.SG View More All News Press Releases SEC Filings Notice of Annual General Meeting in Karolinska Development AB (publ) Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025 Karolinska Development Annual Report 2024 published Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01 Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01 Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface Year-end Report - January-December 2024 Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities